EDITORIAL article
Front. Tuberc.
Sec. Pathogen and Host Biology of Tuberculosis
Volume 3 - 2025 | doi: 10.3389/ftubr.2025.1635563
This article is part of the Research TopicRising Stars in Tuberculosis and Mycobacterial Diseases: 2023View all 7 articles
Editorial: Rising stars in tuberculosis
Provisionally accepted
Harald Gotten Wiker1*
Elsa Anes2
Philippe Clevenbergh3
Seyed Ehtesham Hasnain4
Sven Hoffner5
Alissa Rothchild6
Vishwanath Venketaraman7- 1University of Bergen, Bergen, Norway
- 2Universidade de Lisboa, Lisbon, Portugal
- 3CHU Brugmann, Brussels, Belgium
- 4Indian Institute of Technology Delhi, New Delhi, India
- 5Department of Global Public Health, GPH, Karolinska Institutet, Stockholm, Sweden
- 6University of Massachusetts Amherst, Amherst, United States
- 7Western University of Health Sciences, Pomona, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
MDR-TB is a significant global health challenge due to its complex treatment, high cost, and severe health outcomes. Understanding the mechanisms of drug resistance and addressing the factors contributing to its development are crucial for controlling the spread of MDR-TB. In Sverdlovsk Oblast in Russia, MDR-TB is a considerable problem. Genetic patterns were used to study transmission dynamics of MDR-TB cases by Umpeleva et al (1) (https://www.frontiersin.org/journals/tuberculosis/articles/10.3389/ftubr.2025.1406536 /abstract). The study found that a significant proportion of M. tuberculosis isolates had unique genetic patterns, suggesting minimal recent transmission. The presence of mutations in gyrA/B genes, associated with fluoroquinolone resistance, was more common in isolates with unique patterns, indicating that these mutations may have developed in already drug-resistant strains due to inadequate chemotherapy regimens but had not yet circulated widely, which could be due to biological fitness costs related to these mutations. Investigating the gyrA/B mutations may provide insights into how M. tuberculosis adapts to drug resistance and maintains its transmissibility.M. tuberculosis infection can be transmitted to the fetus via hematogenous spread from the placenta to the umbilical vein or through the aspiration or ingestion of infected amniotic fluid. Congenital TB is a relatively rare condition compared to other forms of TB but carries a high mortality rate. The incidence of congenital TB is higher in regions with high prevalence, such as parts of Asia and Africa. This case report by
Keywords: Mycobacterium tuberculosis, Tuberculosis, Multi drug resistance (MDR), Glutamine metabolism, Antigenic Variation, mucosal immmunity, bacterial fitness, Transcriptional Regulatory Network (TRN)
Received: 26 May 2025; Accepted: 03 Jun 2025.
Copyright: © 2025 Wiker, Anes, Clevenbergh, Hasnain, Hoffner, Rothchild and Venketaraman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Harald Gotten Wiker, University of Bergen, Bergen, Norway
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.